

Supplementary Material

to

Chemoselective Fractionation for Shotgun Proteomics: Global Assessment of
Cysteinylyl Peptide Capture*

De Lin, Jing Li, Robbert J.C. Slebos and Daniel C. Liebler

Synthesis of IBB

Figures S1-S10.

SYNTHESIS OF IBB

^1H and ^{13}C NMR spectra were acquired with a Bruker DPX-300 or AV-400 instrument (Bruker Instruments, Billerica, MA). All reactions were carried out under argon. Anhydrous THF, DMF and Et_3N were either commercial available or dried under in house solvent purification system. Purification by column chromatography was carried out on silica gel and TLC plates were visualized by UV and stained with phosphomolybdic acid. Compounds **2**, **3** and **4** were prepared according to reported procedures. {Rock, 1996 #34}

3-(tert-butyldimethylsilyloxy)benzaldehyde (2). To a solution of 3-hydroxybenzaldehyde (6.1 g, 50 mmol) in THF (150 mL) was added tert-butyldimethylsilyl chloride (TBDMSCl, 9.0 g, 60 mmol). The solution was cooled to 0 °C and triethylamine (8.3 mL, 60 mmol) was added dropwise. A precipitate formed immediately. After stirring overnight, the reaction mixture was filtered and the THF removed under reduced pressure. The crude product was purified by silica gel chromatography (eluent hexane-EtOAc 9:1), affording **2** as a slightly yellow oil (10.1 g, 86%). $^1\text{H-NMR}$ (300 MHz, CD_3Cl) δ 0.24 (s, 6H), 1.02(s, 9H), 7.10-7.16 (m, 1H), 7.28-7.53 (m, 3H), 9.98 (s, 1H); $^{13}\text{C NMR}$ (75 MHz, CD_3Cl) δ -4.50, 18.14, 25.55, 119.81, 123.51, 126.50, 130.02, 137.86, 156.35, 192.08.

1-Hydroxy-1-[3-(tert-butyldimethylsilyloxy)phenyl](2-phenyl-1,3-dithian-2-yl)ethane (3). To a solution of 2-phenyl-1,3-dithiane (7.84g, 40 mmol) in THF (100 mL) at 0 °C under an argon atmosphere was added 16 mL of n-butyllithium (2.5 M in hexane, 40 mmol) dropwise. After 30 min, **2** (9.44g, 40 mmol) was added. The solution was stirred at 0 °C for 1 h, and then quenched by 6N HCl (10 mL). After evaporating the organic solvent, the residue was dissolved

in 200 mL CH₂Cl₂ and washed with brine (2 x 100 mL). The organic phase was dried with NaSO₄ and evaporated under reduced pressure. The resulting oil was crystallized from ethanol/water, affording **3** as white powder (15.7g, 91%). ¹H-NMR (300 MHz, CD₃Cl) δ 0.13 (s, 1H), 0.96 (s, 1H), 1.88-2.00 (2H), 2.61-2.81 (4H), 2.92 (d, 1H, *J* = 3.8 Hz), 4.96 (d, 1H, *J* = 3.6 Hz), 6.39-6.48 (2H), 6.66-6.73 (1H), 6.98 (t, 1H, *J* = 7.8 Hz), 7.23-7.37 (3H), 7.68-7.77 (2H); ¹³C NMR (75 MHz, CD₃Cl) δ -4.42, 18.07, 24.73, 25.63, 26.96, 27.26, 66.43, 80.87, 119.71, 119.93, 121.17, 127.49, 127.81, 128.12, 130.46, 137.37, 138.72, 154.54.

Methyl 2-[3-(hydroxy(2-phenyl-1,3-dithian-2-yl)methyl)phenoxy]acetate (4). To a solution of **3** (10.8g, 25 mmol) and methyl bromoacetate (6.1g, 40 mmol) in dry THF (100 mL) under an argon atmosphere was added 27 mL TBAF (1 M in THF, 17 mmol) dropwise. The solution was stirred overnight, and then the organic solvent was evaporated. The residue was dissolved in 200 mL EtOAc and washed with brine (2 x 100 mL). The organic phase was dried with NaSO₄ and evaporated under reduced pressure. The resulting oil was crystallized from EtOAc/Hexane, affording **4** as white powder (9.1g, 93%). ¹H-NMR (300 MHz, CD₃Cl) δ 1.88-1.98 (2H), 2.60-2.82 (4H), 3.00 (d, 1H, *J* = 3.4 Hz), 3.80 (s, 3H), 4.39 (s, 2H), 4.98 (d, 1H, *J* = 3.2 Hz), 6.33 (s, 1H), 6.58 (d, 1H, *J* = 7.6 Hz), 6.82 (dd, 1H, *J* = 8.2 and 2.6 Hz), 7.07 (t, 1H, *J* = 7.8 Hz), 7.26-7.37 (3H), 7.66-7.74 (2H); ¹³C NMR (75 MHz, CD₃Cl) δ 24.66, 26.91, 27.21, 52.10, 65.12, 80.55, 113.63, 115.25, 121.75, 127.47, 127.93, 128.06, 130.46, 137.36, 138.99, 156.54, 169.22.

N-[2-(2-(2-aminoethoxy)ethoxy)ethyl]-2-[3-(hydroxy(2-phenyl-1,3-dithian-2-yl)methyl)phenoxy]acetamide (5). To a solution of **4** (3.9g, 10 mmol) in 400 mL methanol was added 2,2'-(Ethylenedioxy)bisethylamine (5.9 g, 40 mmol). The solution was stirred overnight,

and then the organic solvent was evaporated. The crude product was purified by silica gel chromatography (eluent CH₂Cl₂-MeOH-NH₄OH 50:50:1), affording 6 as a slightly yellow oil (3.8 g, 75%). ¹H-NMR (300 MHz, MeOH-*d*₄) δ 1.76-1.96 (2H), 2.52-2.82 (6H), 3.47 (t, 2H, *J* = 5.4 Hz), 3.52 (t, 2H, *J* = 5.3 Hz), 3.59 (t, 2H, *J* = 5.3 Hz), 3.62 (s, 4H), 4.23 (s, 2H), 4.98 (s, 1H), 6.37 (s, 1H), 6.58 (d, 1H, *J* = 7.6 Hz), 6.83 (dd, 1H, *J* = 8.2 and 2.6 Hz), 7.04 (t, 1H, *J* = 8.0 Hz), 7.26-7.32 (3H), 7.71-7.77 (2H); ¹³C NMR (75 MHz, MeOH-*d*₄) δ 24.7, 26.7, 26.8, 38.5, 40.7, 65.3, 66.7, 69.0, 69.8, 69.9, 72.1, 80.3, 114.0, 114.5, 122.0, 126.9, 127.4, 127.5, 130.9, 137.6, 140.8, 156.4, 169.6.

N-[2-(2-(2-aminoethoxy)ethoxy)ethyl]-2-[3-(hydroxy(2-phenyl-1,3-dithian-2-yl)methyl)phenoxy]acetamide (6). To a solution of biotin (540 mg, 2.2 mmol) in 10 mL DMF was added 1,1'-carbonyldiimidazole (360 mg, 2.2 mmol). After 30 min, the amine **5** (1.01 g, 2 mmol) was added to the reaction mixture and stirred overnight. The solution was concentrated under high vacuum. The crude product was purified by silica gel chromatography (eluent CH₂Cl₂-MeOH 9:1), affording 6 as a slightly yellow oil (820 mg, 56%). ¹H-NMR (300 MHz, MeOH-*d*₄) δ 1.37-1.50 (2H), 1.52-1.80 (4H), 1.82-1.95 (2H), 2.22 (t, 2H, *J* = 7.2 Hz), 2.54-2.75 (4H), 2.71 (d, 1H, *J* = 12.6 Hz), 2.93 (dd, 1H, *J* = 12.6 and 4.9 Hz), 3.15-3.25 (m, 1H), 3.47 (t, 2H, *J* = 5.4 Hz), 3.55 (t, 2H, *J* = 5.4 Hz), 3.62 (t, 2H, *J* = 5.4 Hz), 3.62 (s, 4H), 4.24 (s, 2H), 4.30 (dd, 1H, *J* = 7.8 and 4.4 Hz), 4.49 (dd, 1H, *J* = 7.8 and 4.8 Hz), 4.98 (s, 1H), 6.38 (s, 1H), 6.58 (d, 1H, *J* = 7.6 Hz), 6.83 (dd, 1H, *J* = 8.2 and 2.6 Hz), 7.04 (t, 1H, *J* = 8.0 Hz), 7.26-7.34 (3H), 7.71-7.77 (2H); ¹³C NMR (75 MHz, MeOH-*d*₄) δ 24.7, 25.4, 26.7, 26.8, 28.1, 28.3, 35.3, 38.5, 38.9, 39.7, 55.6, 60.2, 61.9, 65.3, 66.7, 69.0, 69.2, 69.9, 80.3, 114.0, 114.5, 122.0, 126.9, 127.4, 127.5, 130.9, 137.6, 140.7, 156.3, 164.6, 169.6, 174.7.

N-(2-(2-(2-(2-(3-(hydroxy(2-phenyl-1,3-dithian-2-yl)methyl)phenoxy)acetamido)ethoxy)ethoxy)ethyl)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide (7). To a solution of **6** (510 mg, 0.7 mmol) in 40 mL 9:1 (v/v) acetonitrile/water was added mercury(I) perchlorate tetrahydrate (790 mg, 2.1 mmol). After stirred for 5 min at room temperature, the solution was quenched by NaS₂O₄ (5%, 10mL), diluted by methanol and filtered, and then washed by NaHCO₃ and brine. The crude product was purified by silica gel chromatography (eluent CH₂Cl₂-MeOH 8:1), affording **7** as a white solid (310 mg, 69%). ¹H-NMR (300 MHz, MeOH-*d*₄) δ 1.35-1.49 (2H), 1.52-1.80 (4H), 1.82-1.95 (2H), 2.20 (t, 2H, *J* = 7.2 Hz), 2.70 (d, 1H, *J* = 12.8 Hz), 2.91 (dd, 1H, *J* = 12.8 and 4.9Hz), 3.14-3.23 (m, 1H), 3.46 (t, 2H, *J* = 5.2 Hz), 3.53 (t, 2H, *J* = 5.4 Hz), 3.57 (t, 2H, *J* = 5.4 Hz), 3.58 (s, 4H), 4.28 (dd, 1H, *J* = 7.6 and 4.4 Hz), 4.47 (dd, 1H, *J* = 7.6 and 4.8 Hz), 4.50 (s, 2H), 6.12 (s, 1H), 6.90 (d, 1H, *J* = 8.0 Hz), 7.06-7.13 (m, 2H), 7.28 (t, 1H, *J* = 8.0 Hz), 7.44 (t, 1H, *J* = 8.0 Hz), 7.56 (t, 1H, *J* = 7.2 Hz), 7.99 (d, 1H, , *J* = 6.6 Hz); ¹³C NMR (75 MHz, MeOH-*d*₄) δ 25.37, 28.02, 28.29, 29.77, 35.27, 38.44, 38.84, 39.59, 55.53, 60.14, 61.88, 66.81, 68.98, 69.14, 69.81, 75.75, 113.88, 114.20, 120.90, 128.27, 128.62, 129.74, 133.19, 134.47, 140.85, 158.00, 164.63, 169.53, 174.68, 198.00. MS (ESI) calcd for C₃₂H₄₃N₄O₈S (MH⁺) 643.28, found 643.33.

N-(2-(2-(2-(2-(3-(1-hydroxy-2-oxo-2-phenylethyl)phenoxy)acetamido)ethoxy)ethoxy)-ethyl)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide (8). To a solution of **7** (320 mg, 0.5 mmol) and iodoacetic acid (280 mg, 1.5 mmol) in 20 mL CH₂Cl₂ was added DCC (270 mg, 1.3 mmol) and DMAP (6 mg, 0.05 mmol). After 2.5 h, the resulting suspension was filtered, and the filtrate was diluted with CH₂Cl₂. The organic phase was washed with NaHCO₃ and brine, dried with NaSO₄. The crude product was purified by silica gel chromatography (eluent CH₂Cl₂-MeOH 9:1), affording **8** as a white solid (330 mg, 81%). ¹H-NMR (300 MHz,

CDCl_3 δ 1.32-1.47 (2H), 1.55-1.78 (4H), 2.20 (t, 2H, $J = 7.2$ Hz), 2.70 (d, 1H, $J = 12.7$ Hz), 2.86 (dd, 1H, $J = 12.8$ and 4.8 Hz), 3.04-3.15 (m, 1H), 3.37-3.62 (12H), 3.85 (s, 2H), 4.26 (dd, 1H, $J = 7.1$ and 4.8 Hz), 4.41-4.49 (m, 1H), 4.48 (s, 2H), 5.79 (s, 1H), 6.66 (s, 1H), 6.73 (t, 1H, $J = 5.3$ Hz), 6.84 (s, 1H), 6.91 (dd, 1H, $J = 8.1$ and 2.3 Hz), 7.07 (s, 1H), 7.09-7.18 (m, 2H), 7.32 (t, 1H, $J = 7.8$ Hz), 7.42 (t, 1H, $J = 7.8$ Hz), 7.55 (t, 1H, $J = 7.0$ Hz), 7.93 (d, 1H, $J = 8.0$ Hz); ^{13}C NMR (75 MHz, $\text{MeOH-}d_4$) δ 25.55, 28.02, 28.20, 35.92, 38.76, 39.04, 40.46, 55.61, 60.12, 61.70, 67.60, 69.55, 69.86, 69.98, 70.05, 78.21, 115.21, 115.34, 122.22, 128.78, 130.54, 133.84, 134.15, 134.65, 157.62, 164.07, 167.93, 168.16, 173.35, 192.84. MS (ESI) calcd for $\text{C}_{34}\text{H}_{43}\text{IN}_4\text{NaO}_9\text{S}$ (M + Na) 833.17, found 833.17

Figure S1. MS/MS spectrum of model peptide (I), Ac-AVAGCAGAR (Ac-TpepC).

TpepC #342 RT: 10.78 AV: 1 NL: 1.92E7
T: + c ESI Full ms2 817.40@cid35.00 [225.00-2000.00]




Figure S2. MS/MS spectrum of model peptide IBB conjugate (**II**, Ac-TrepC-IBB).

TrepC-IBB_090828143932 #482 RT: 15.21 AV: 1 NL: 2.15E6
T: + c ESI Full ms2 750.30@cid25.00 [205.00-2000.00]




Figure S3. MS/MS spectrum of model peptide IAA conjugate (**V**, Ac-TpepC-IAA).

TpepC-IAA #342 RT: 10.79 AV: 1 NL: 2.17E6
T: + c ESI Full ms2 875.50@cid35.00 [240.00-2000.00]




Figure S4. Distribution of theoretical amino acid containing peptides level from *in silico* tryptic digestion of the IPI Human database version 3.37 (■) and the *Saccharomyces* Genome database (●).




Figure S5. Relationship between IBB enrichment effect and Met-peptide abundance in yeast (A) and RKO cell (B) proteins. the protein index (x-axis) was sorted by increasing detected Met-peptide abundance. The listed r values are Spearman correlation coefficients for proteins with at least one predicted or detected Met-peptide.




Figure S6. Correlation between protein abundance (cell copy number) and spectral counts in yeast global (G) fraction. Protein protein expression data are from (Ghaemmaghami et al. (2003) *Nature* 425: 737-741). Spearman $r = 0.55$, p (two-tailed) < 0.0001 .




Figure S7. Correlation between theoretical Cys-peptide fraction and protein abundance (cell copy number) and in yeast global (G) fraction. Protein protein expression data are from (Ghaemmaghami et al. (2003) *Nature* 425: 737-741). Spearman $r = -0.097$.




Figure S8. Comparison of distributions across cellular components for identified RKO cell proteins from global (G) and elute (E) fractions. Assignment to GO classifications was done with the WebGestalt gene analysis tool (Zhang et al. (2005) *Nucleic Acids Res* **33**, W741-748). A total of 4887 identified proteins were annotated to 4668 unique genes, among which 4173 genes were identified in global sample and 3407 genes were identified in elute sample.




Figure S9. Comparison of distributions across biological processes for identified RKO cell proteins from global (G) and elute (E) fractions. Assignment to GO classifications was done with the WebGestalt gene analysis tool (Zhang et al. (2005) *Nucleic Acids Res* **33**, W741-748).




Figure S10. Comparison of distributions across molecular functions for identified RKO cell proteins from global (G) and elute (E) fractions. Assignment to GO classifications was done with the WebGestalt gene analysis tool (Zhang et al. (2005) *Nucleic Acids Res* **33**, W741-748).

